Evidence map›Paper›PMID 36871629›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023

Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.

Amy P Rossi, Simon Tremblay, Cyd M Castro-Rojas, Ashley A Burg, Krishna M Roskin, Jenna M Gehman, Adele Rike-Shields, Rita R Alloway, Paul Brailey, David Allman and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Amy P RossiImmunology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Simon TremblayDivision of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Cyd M Castro-RojasDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Ashley A BurgDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Division of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Krishna M RoskinDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Jenna M GehmanDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Adele Rike-ShieldsDivision of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; The Christ Hospital, Cincinnati, Ohio, USA.
Rita R AllowayDivision of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Paul BraileyTransplant Immunology Division, Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, USA.
David AllmanDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David A HildemanDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Electronic address: David.hildeman@cchmc.org.
E Steve WoodleDivision of Transplantation, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Electronic address: woodlees@ucmail.uc.edu.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · USChrist Hospital · USUniversity of Cincinnati Medical Center · USUniversity of Pennsylvania · US

Funding

Tissue Repository CoreP30AR070549 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Leah Claire Kottyan · 2016 to 2026
$7.7M
Proteasome Targeting for Alloreactive Plasma CellsR01AI154932 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, HILDEMAN, DAVID A · 2020 to 2025
$7.2M
NIAID NIH HHS R01 AI154932NIAMS NIH HHS P30 AR070549
6 · The paper itself

Abstract

To date, plasma cell (PC)-targeted therapies have been limited by suboptimal PC depletion and antibody rebound. We hypothesized this is partly because of PC residence in protective bone marrow (BM) microenvironments. The purpose of this proof-of-concept study was to examine the effects of the CXCR4 antagonist, plerixafor, on PC BM residence; its safety profile (alone and in combination with a proteasome inhibitor, bortezomib); and the transcriptional effect on BMPCs in HLA-sensitized kidney transplant candidates. Participants were enrolled into 3 groups: group A (n = 4), plerixafor monotherapy; and groups B (n = 4) and C (n = 4), plerixafor and bortezomib combinations. CD34

Indexed as

Heterocyclic CompoundsKidney TransplantationAnimalsBone MarrowBoronic AcidsBortezomibHematopoietic Stem Cell MobilizationHumansMicePilot ProjectsPlasma CellsProteasome Endopeptidase ComplexProteasome InhibitorsPyrazinesReceptors, CXCR4Boronic AcidsBortezomibCXCR4 protein, humanHeterocyclic CompoundsProteasome Endopeptidase ComplexProteasome InhibitorsPyrazinesReceptors, CXCR4antibodybortezomibdesensitizationdonor-specific antibodiesDSAHLA antibodieskidney transplantplasma cellsplerixaforproteasome inhibitorssingle-cell genomics

Identifiers

PMID36871629
PMCPMC10259505
OpenAlexW4323075051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.